RA0365

antibody from Oursmab

Targeting: IL23A IL-23, IL-23A, IL23P19, P19, SGRF

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0365

Provider

Oursmab

Product name

Brazikumab (Biosimilar Reference Antibody) (IL23A)

Antibody type

Monoclonal

Description

Brazikumab is a humanized monoclonal antibody designed to specifically target the p19 subunit of interleukin-23 (IL-23). It functions as an antagonist by binding to IL-23p19, thereby blocking its interaction with the IL-23 receptor complex. This inhibits the downstream signaling of IL-23, a key cytokine that drives the differentiation, expansion, and maintenance of pathogenic T helper 17 (Th17) cells. It has been primarily investigated as a potential therapeutic for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD), representing a strategy to target a specific pathway within the broader IL-12/IL-23 axis implicated in inflammatory bowel disease (IBD) pathogenesis.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Brazikumab (Biosimilar Reference Antibody) (IL23A)-RA0365-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Brazikumab (Biosimilar Reference Antibody) (IL23A)-RA0365 in a linear range of 3.91-125 ng/mL.